(Reuters) -Moderna on Wednesday said its flu vaccine had generated a stronger immune response against all four A and B strains of the influenza virus compared to traditional flu shots in a late ...

新型コロナウイルスのmRNAワクチンを開発したことで知られる製薬企業のモデルナが、季節性インフルエンザのmRNAワクチン「mRNA-1010」の第3相臨床試験で、従来の標準的なインフルエンザワクチンよりも相対的に26.6％高い有効性が確認されたと発表 ...

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine | Moderna, Inc. https: ...

The Trump administration has canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, the drugmaker ...

Developing single-dose combination shots against Covid-19 and other respiratory diseases will be a business direction in the future, per Moderna’s plans. A combination vaccine against Covid-19 and flu ...

2009年にFDAより3価インフルエンザワクチンとして承認を受けたFluzone High-Dose（Influenza Vaccine）は、2種類のA型ウイルス株と1種類のB型ウイルス株で構成されている製品です。Fluzone High-Dose Quadrivalentは、3価ワクチンに1種類のB型ウイルス株を追加した4価のワクチンです。Fluzone High-Dose ...

According to experts, the situation is even more complicated than it seems because many people contract influenza and Covid-19 at the same time. International pharmaceutical giants, such as Pfizer, ...

Takeda Pharmaceutical Co. says it has begun clinical trials in Japan of a COVID-19 vaccine candidate by U.S. biotech firm Moderna Inc. with an eye to distributing it in the first half of this year. ..

モデルナは7日、最大5億ドル（約550億円）を投じてアフリカに新たな製造工場を建設し、ワクチン不足に悩むアフリカ大陸に同社の新型コロナ ...